Zentalis Pharmaceuticals, Inc. (ZNTL)
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$137.1M
- Total assets
- $289.0M
- Market cap
- $260.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $152.8M
- Operating income
- -$152.8M
- Income tax
- $442.0K
- Net income
- -$137.1M
- EPS (basic)
- $-1.91
- EPS (diluted)
- $-1.91
Balance sheet
- Total assets
- $289.0M
- Current assets
- $253.2M
- Total liabilities
- $72.8M
- Current liabilities
- $36.6M
- Shareholders’ equity
- $216.2M
Cash flow
- Operating cash flow
- -$125.2M
- Investing cash flow
- $131.6M
- Financing cash flow
- -$4.3M
- Net cash flow
- $2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $260.5M
- EPS (diluted)
- $-1.91
- Shares outstanding
- 60.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 3, 2020
Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price
- Reported a net loss of $137.1M in FY2025.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zentalis Pharmaceuticals, Inc..
Write a review
News about Zentalis Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Zentalis Pharmaceuticals, Inc.: frequently asked questions
Is Zentalis Pharmaceuticals, Inc. an American company?
Zentalis Pharmaceuticals, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Zentalis Pharmaceuticals, Inc. headquartered?
Zentalis Pharmaceuticals, Inc. is headquartered in San Diego, California, United States.
Is Zentalis Pharmaceuticals, Inc. publicly traded?
Yes — Zentalis Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol ZNTL on the NASDAQ.
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Zentalis Pharmaceuticals, Inc. founded?
Zentalis Pharmaceuticals, Inc. was founded in 2014.
